Showing 321-330 of 5790 results for "".
DermWire TV: Focus on Skin Cancer Awareness
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwire-tv-focus-on-skin-cancer-awareness/19613/For skin cancer awareness month, the AAD rolls out a new campaign, urging the public to “Practice Safe Sun.” The Skin Cancer Foundation is 40! Founded in 1979, the foundation made its mark in 1983 when it introduced its seal for sunscreens. SCF President, Deborah Sarnoff, MD discusses the foundationTips on Expanding Your Practice Focus to Men
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-on-expanding-your-practice-focus-to-men/18699/“I see the male patient as a huge opportunity I think men have been largely overlooked,” says Terrence Keaney, MD. He explains what procedures and services appeal to men, talks about the fundamentals of building a male-friendly practice, and offers tips to make male patients more comfortable undergoAubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tMohs Certification: Finding a Middle Ground
https://practicaldermatology.com/topics/practice-management/mohs-certification-finding-a-middle-ground/18681/Can specialists reach a consensus on Mohs certification? Joel Schlessinger, MD, FAAD certainly hopes so. He spoke with DermTube.com about the controversy over certification for the surgical technique to treat skin cancer and urged compromise.Restylane Silk Launches; Xeljanz to FDA
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-restylane-silk-launches-xeljanz-to-fda/18970/This edition of DermWireTV covers the launch of Restylane Silk from Galderma for the treatment of lips and FDA acceptance of the NDA for Pfizer's Xeljanz (tofacitinib) for adults with psoriasis. Plus, new data from the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) show incrTake 5: Recent Findings in Acne Research
https://practicaldermatology.com/columns/take-5/take-5-recent-findings-in-acne-research/21733/Five new studies examine potentially useful therapies and strategies to improve adherence.Cosmetics Challenge: Going with the Flow: An Overview and Clinical Discussion of The Rheology of Soft Tissue Fillers, Part 1 of 2
https://practicaldermatology.com/topics/general-topics/cosmetics-challenge-going-with-the-flow-an-overview-and-clinical-discussion-of-the-rheology-of-soft-tissue-fillers-part-1-of-2/21890/Flow properties and the clinical behavior that these properties predict can be important factors that help clinicians refine and individualize treatment with dermal fillers.Residents' Reports: A Comparison of Fractional Resurfacing Lasers
https://practicaldermatology.com/topics/general-topics/residents-reports-a-comparison-of-fractional-resurfacing-lasers/21966/Practitioners considering an investment in resurfacing lasers may benefit from this comparison of key system features.ASDS: Dr. Farah on Hair Loss Treatment Options
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-farah-hair-regrowth-options/29152/Ronda Farah, MD, discusses treatment options for hair loss, including platelet-rich plasma and lasers, at the 2024 American Society for Dermatologic Surgery Annual Meeting.FDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.